This podcast will discuss the combination of azacitidine and pembrolizumab in patients with higher-risk MDS, a personalized prediction model based on clinical and genomic data, the classification of therapy-related MDS as well as the importance of platelet counts as a prognostic factor.

Topics:

• Azacitidine with Pembrolizumab in Intermediate-1 or Higher-Risk MDS
• Personalized Prediction Model in MDS
• Therapy-Related MDS Deserves Specific Sub-classification
• Influence of Platelet Count on Prognosis in MD

Listen

Links

• https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.17689
• https://ascopubs.org/doi/abs/10.1200/JCO.20.02810
• https://www.nature.com/articles/s41375-020-0917-7
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440262/